Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ Origin: Appendix \ 5 \ Amended \ o1/o7/98, o1/o9/99, o1/o7/o0, 30/o9/o1, 11/o3/o2, o1/o1/o3, 24/10/o5, o1/o8/12, o4/o3/13, o1/o8/12, o1/o8/1$

Name of entity

Quantum Energy Limited

ABN

19 003 677 245

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

I +Class of +securities issued or to be issued

Fully Paid Ordinary Shares

⁺ See chapter 19 for defined terms.

2 Number of *securities is be issued (if known) or number which may be iss	maximum 20,000,000 Fully Paid Ordinary Shares are
	 As set out in the Company's Announcements in relation to Quantum Healthcare Pty Limited (QHC) dated 5 April 2018 and 3 October 2018: if QHC achieves EBIT of greater than A\$11 million for the two year period from 1 July 2017 to 30 June 2019, the Company will on 30 September 2019 issue a further 30 million QTM Shares at 2.4 cents per share, and a further Appendix 3B will be lodged on 30 September 2019 if the QHC EBIT target is achieved and the additional 30 million shares are issued on that date.

⁺ See chapter 19 for defined terms.

- 3 Principal terms of the ⁺securities (e.g. if options, exercise price and expiry date; if partly paid ⁺securities, the amount outstanding and due dates for payment, if ⁺convertible securities, the conversion price and dates for conversion)
- Same as existing Fully Paid Ordinary Shares: except a voluntary escrow applies to the newly issued 20 million Shares for a period of 2 years from their issue date until 3 October 2020, during which escrow period the holders of the 20 million shares have agreed they will not:
- dispose of, or agree or offer to dispose of such shares;
- create, or agree or offer to create, any security interest in such shares, or
- do or omit to do any act if the act or omission would have the effect of transferring effective ownership or control of such shares
- If the respective EBIT target referred to in item 2 above is achieved and a further 30 million QTM shares are issued by the Company on 30 September 2019, such further shares will be subject to a two year voluntary escrow from 30 September 2019 to 30 September 2021 on the same escrow terms set out above.

⁺ See chapter 19 for defined terms.

4	 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	Yes
5	Issue price or consideration	2.4 cents per Share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	QTM has issued the 20 million Fully Paid Ordinary Shares (and agreed to the conditional issue of a further 30 million Fully Paid Ordinary Shares on 30 September 2019) under an Acquisition Agreement dated 5 April 2018 under which QTM has received a transfer of the 20% minority shareholding held by the Sellers in Quantum Healthcare Pty Limited (QHC), which has resulted in QHC becoming a 100% wholly owned subsidiary of QTM
6a	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in</i> <i>relation to the ⁺securities the</i> <i>subject of this Appendix 3B</i> , and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A

⁺ See chapter 19 for defined terms.

- 6c Number of *securities issued without security holder approval under rule 7.1
- 6d Number of +securities issued with security holder approval under rule 7.1A
- 6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of +securities issued under an exception in rule 7.2
- 6g If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.
- 6h If ⁺securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

7 ⁺Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

N/A

N/A

N/A

N/A

N/A

N/A

3 October 2018

Number

+Class

⁺ See chapter 19 for defined terms.

8	8 Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in section	1,098,308,291	•	d Ordinary Shares
	2 if applicable)		is c F n s is C	ne existing ssued shares of 078,308,291 olus the 20 nillion hares being ssued on 3 October 018)

⁺ See chapter 19 for defined terms.

9 Number and ⁺class of all ⁺securities not quoted on ASX (*including* the ⁺securities in section 2 if applicable)

Number	+Class
NT:1	
Nil	

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)
 Same as existing Fully Paid Ordinary Shares from date of issue.

Part 2 - Pro rata issue

II	Is security holder approval N/A required?
12	Is the issue renounceable or non- renounceable?
13	Ratio in which the ⁺ securities will N/A be offered
14	+Class of +securities to which the N/A offer relates
15	*Record date to determine N/A entitlements
16	Will holdings on different registers N/A (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in N/A relation to fractions
18	Names of countries in which the entity has security holders who will not be sent new offer documents
	Note: Security holders must be told how their entitlements are to be dealt with.
	Cross reference: rule 7.7.
19	Closing date for receipt of N/A acceptances or renunciations

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

		NT / 4
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or	N/A
	commission	
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the	N/A
-3	broker to the issue	1 1/2 1
24	Amount of any handling fee payable	N/A
	to brokers who lodge acceptances	
	or renunciations on behalf of	
	security holders	
	If the issue is contingent on convert	
25	If the issue is contingent on security holders' approval, the date of the	N/A
	meeting	
	inceeding	
26	Date entitlement and acceptance	N/A
	form and offer documents will be	,
	sent to persons entitled	
27	If the entity has issued options, and	N/A
	the terms entitle option holders to	
	participate on exercise, the date on which notices will be sent to option	
	holders	
28	Date rights trading will begin (if	N/A
	applicable)	
29	Date rights trading will end (if	N/A
	applicable)	
30	How do security holders sell their	N/A
5	entitlements <i>in full</i> through a	· ·
	broker?	
31	How do security holders sell part of	N/A
	their entitlements through a broker	
	and accept for the balance?	

⁺ See chapter 19 for defined terms.

32 How do security holders dispose of their entitlements (except by sale through a broker)?

33 ⁺Issue date

Ī	N/A	
e	N/A	

N/A

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of *securities (tick one)
(a) ✓ *Securities described in Part I
(b) All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35

36

- If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
- If the ⁺securities are ⁺equity securities, a distribution schedule of the additional ⁺securities setting out the number of holders in the categories

I - I,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37

A copy of any trust deed for the additional ⁺securities

⁺ See chapter 19 for defined terms.

Entities	that	have	ticked	box	34(b)
----------	------	------	--------	-----	------	---

38	Number of ⁺ securities for which ⁺ quotation is sought	N/A	
39	⁺ Class of ⁺ securities for which quotation is sought	N/A	
40	Do the ⁺ securities rank equally in all respects from the ⁺ issue date with an existing ⁺ class of quoted ⁺ securities? If the additional ⁺ securities do not rank equally, please state: • the date from which they do • the extent to which they	N/A	
	 participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 		
4 ^I	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period	N/A	
	(if issued upon conversion of another +security, clearly identify that other +security)		
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)	Number N/A	+Class

⁺ See chapter 19 for defined terms.

Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the 'securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 3 October 2018

Print name:

John Walstab (Director/Company secretary)

-- -- -- -- --

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Г

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figu capacity is calculated	<i>ire from which the placement</i>	
<i>Insert</i> number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	N/A	
 Add the following: Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items Subtract the number of fully paid ⁺ordinary securities cancelled during that 12 month 	N/A	
period "A"	N/A	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15	N/A	
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1	
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	N/A	
• Under an exception in rule 7.2		
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	N/A	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	N/A	
Note: number must be same as shown in Step 2		
Subtract "C"	N/A	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	N/A	
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
<i>Multiply</i> "A" by 0.10	N/A
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	N/A
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	
"E"	N/A

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	N/A
Note: number must be same as shown in Step 2	
Subtract "E"	N/A
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	N/A
	Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.